TICKERNERD
Menu
MGXMGXHealthcare · Biotechnology

MGX Stock Forecast: Metagenomi Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$1.16
0.00% on the day

The 5 Wall Street analysts covering Metagenomi Therapeutics, Inc. hold a median 12-month price target of $7 — +503.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$43.8M
Ticker Nerd rank
30 / 100
Median analyst target
$7.00
Analysts covering
5
Revenue−$257K−103.0% y/y
Operating income−$28.8M
Net income−$27.5M
Free cash flow−$19.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
0.0%
1M
−4.1%
YTD
−28.4%
1Y
−38.6%
From 52W high
−65.4%
From 52W low
+1.8%
$1.14
$3.35
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MGX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Metagenomi Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
30 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
85
Size
83
Accruals
71
Quality
40
Volatility
31
Momentum
27
Revisions
26
Growth
19
Value
11

Issuance (85): The share count has been shrinking and the company is not leaning on new borrowing.

Value (11): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MGX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MGX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26MGXHigh $9.00Median $7.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
4 Buy1 Hold0 Sell
Low $5.00Median $7.00High $9.00

The green dot is the last close — the median target sits +503.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 Aug 2026Wells FargoMaintainsOverweight$9.00 → $7.00
7 July 2026Chardan CapitalMaintainsBuy$7.00 → $5.00
7 July 2026Chardan CapitalMaintainsBuy—
12 May 2026Wells FargoMaintainsOverweight—
19 Aug 2025HC Wainwright & Co.ReiteratesBuy—
15 Aug 2025Chardan CapitalMaintainsBuy—
14 Aug 2025Wells FargoMaintainsOverweight—
15 May 2025Chardan CapitalMaintainsBuy—
14 May 2025Wells FargoMaintainsOverweight—
3 Apr 2025HC Wainwright & Co.MaintainsBuy—
18 Mar 2025Wells FargoMaintainsOverweight—
10 Dec 2024HC Wainwright & Co.MaintainsBuy—
21 Nov 2024HC Wainwright & Co.ReiteratesBuy—
20 Nov 2024Chardan CapitalMaintainsBuy—
15 Oct 2024HC Wainwright & Co.ReiteratesBuy—
6 Sept 2024HC Wainwright & Co.ReiteratesBuy—
5 Sept 2024Chardan CapitalMaintainsBuy—
21 Aug 2024HC Wainwright & Co.MaintainsBuy—
19 Aug 2024Chardan CapitalMaintainsBuy—
15 Aug 2024BMO CapitalMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MGX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MGX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Metagenomi Therapeutics, Inc. returned −38.6% against +17.5% for the S&P 500, dividends included.

MGX vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160180Oct 25Jan 26Apr 26Jul 26MGXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MGX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

Metagenomi Therapeutics, Inc. (MGX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.5×

Cheaper than 80% of US stocks

Price / sales
3.2×

Cheaper than 39% of US stocks

Price / book
0.4×

Cheaper than 87% of US stocks

EV / EBITDA
0.4×

Cheaper than 59% of US stocks

Growth & margins
Revenue growth (YoY)
−120.6%

Higher than 1% of US stocks

Earnings growth (YoY)
−103.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
11195.7%

Higher than 99% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−60.6%

Higher than 19% of US stocks

Return on assets
−28.2%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Metagenomi Therapeutics, Inc. (MGX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Metagenomi Therapeutics, Inc. has a market value of $43.8M and an enterprise value of −$39.1M.

  • Revenue in the twelve months to 30 June 2026: $13.6M. The latest quarter shrank 120.6% year on year.

  • Net income over the same four quarters: −$93.5M, a −689.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$85.8M.

  • Shares outstanding: 37.8M.

  • Trailing P/E: −0.5×; forward P/E: −0.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Metagenomi Therapeutics, Inc. employs 113 people — $120K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

MGX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MGXMetagenomi Therapeutics, Inc.$43.8M
30
ATNMActinium Pharmaceuticals, Inc.$43.9M
73
ATYRaTyr Pharma, Inc.$42.2M
49
VERUVeru, Inc.$41.6M
34
TVGNTevogen, Inc.$47.2M
15
CELUCelularity, Inc.$39.9M
19
ANVSAnnovis Bio, Inc.$47.6M
25

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Metagenomi Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MGX news & analysis

Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference

GlobeNewsWire · 1 Sept 2026neutral

Metagenomi Therapeutics, Inc. announced that Jian Irish, Ph.D., will present at the Wells Fargo 21st Annual Healthcare Conference. The presentation relates to the company's in vivo genome editing technologies aimed at developing curative genetic medicines.

Why it matters — An upcoming presentation at a major healthcare conference offers Metagenomi a platform to communicate about its gene editing programs to the investment community.

Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

PRNewsWire · 25 Aug 2026negative

A law firm is urging Metagenomi Therapeutics, Inc. shareholders to contact them regarding potential breaches of fiduciary duties by company insiders, noting there may be limited time to enforce shareholder rights. The firm states it would handle the matter on a contingent fee basis with no out-of-pocket legal costs to shareholders.

Why it matters — MGX watchers would care because the notice signals a potential shareholder lawsuit or investigation into alleged insider misconduct, which could affect the company's legal and reputational standing.

Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · 10 Aug 2026negative

Metagenomi Therapeutics reported a quarterly loss of $0.73 per share for Q2, which was wider than the Zacks Consensus Estimate of a $0.63 loss. This compares with a loss of $0.54 per share in the same period a year ago, meaning its revenue fell short of estimates.

Why it matters — MGX watchers would care because the company posted a larger-than-expected quarterly loss and missed revenue estimates, indicating weaker-than-anticipated financial performance for the period.

FAQ

Frequently asked questions about MGX stock

What is the MGX stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Metagenomi Therapeutics, Inc. have a median 12-month price target of $7, with estimates ranging from $5 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MGX stock a buy right now?

Of the 5 analysts covering Metagenomi Therapeutics, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Metagenomi Therapeutics, Inc. 30 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MGX?

As at 12 Sept 2026, Metagenomi Therapeutics, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (85 of 100).

Will MGX stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +503.4% from the last close, and Ticker Nerd's factor model ranks Metagenomi Therapeutics, Inc. 30 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MGX stock forecast for 2030?

No analyst covering Metagenomi Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MGX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $9 over the next 12 months.

How has MGX stock performed over the past year?

Metagenomi Therapeutics, Inc. returned -38.6% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Metagenomi Therapeutics, Inc. do?

Metagenomi Therapeutics, Inc. is a precision genetic medicines company focused on in vivo genome editing for the development of curative therapies.

What is the latest news on MGX?

The most recent item we track (GlobeNewsWire, 1 Sept 2026): "Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference". Metagenomi Therapeutics, Inc. announced that Jian Irish, Ph.D., will present at the Wells Fargo 21st Annual Healthcare Conference. The presentation relates to the company's in vivo genome editing technologies aimed at developing curative genetic medicines.

Company

About Metagenomi Therapeutics, Inc.

Metagenomi Therapeutics, Inc. is a precision genetic medicines company focused on in vivo genome editing for the development of curative therapies. The company uses a proprietary metagenomics-derived toolbox to discover and engineer genome-editing systems, including nucleases, base editors, and gene-integration technologies. Its platform is designed to support precise DNA changes across a wide range of genetic targets, with current work centered on therapeutic programs for serious inherited conditions such as hemophilia and other genetic diseases. Metagenomi Therapeutics also collaborates with partners in biotechnology and pharmaceutical research to expand the potential uses of its editing technologies. Headquartered in Emeryville, California, Metagenomi Therapeutics, Inc. plays a role in the growing field of next-generation genetic medicine, where genome editing is being developed as a foundational approach to treating disease at its source.

CEO Dr. Jian Irish M.B.A., Ph.D. · 113 employees · United States · https://metagenomi.co